If the stats on its clinical risks are so negative, why is diabetes drug Avandia still on the U.S. market? Well, according to blogger John Mack, a pharma industry insider who keeps a close eye on these things, the answer may have more to do with politics than medicine. As things stand, European regulators have […]
